Key result
Direct oral anticoagulants are generally preferred over vitamin K antagonists for stroke prevention in patients with atrial fibrillation and comorbidities, requiring individualized selection and dosing.
Why the study?
Anticoagulant therapy for the prevention of stroke and systemic embolism presents challenges in patients with atrial fibrillation and complex comorbidities or high risks of emergency surgery and injury.
Answers are grounded in this paper and cite their sources.
This review provides comprehensive guidance on selecting optimal antithrombotic therapy for atrial fibrillation patients with complex comorbidities, generally favoring DOACs while emphasizing individualized risk assessment.
The review discusses the problem of anticoagulant therapy for the prevention of stroke and systemic embolism in patients with atrial fibrillation and comorbidities (hypertension, heart defects, including after heart valve surgery, coronary artery disease, diabetes mellitus, chronic kidney disease, gastrointestinal diseases, anemia, cancer), as well as with a high risk of emergency operations and injuries.
No takes yet. Share an insight, caveat, or question.
Schlyakhto et al. (2021) conducted a review in Atrial fibrillation and comorbidities. Direct oral anticoagulants (DOACs) vs. Vitamin K antagonists (VKAs) was evaluated. Direct oral anticoagulants are generally preferred over vitamin K antagonists for stroke prevention in patients with atrial fibrillation and comorbidities, requiring individualized selection and dosing.
Synapse has enriched 10 related papers. Consider them for comparative context: